Lymphoma
Brief Introduction of CAR-T Cell Therapy Brexucabtagene Autoleucel(Tecartus)
On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Brexucabtagene Autoleucel (Tecartus), a CD19-directed, genetically modified autologous T-cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
May 13th,2024
Lymphoma
Legend Biotech Carvykti®, a Breakthrough CAR-T Cell Therapy
Carvykti® (cilta-cel, Ciltacabtagene Autoleucel) is the first CAR-T cell therapy to receive a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the second-line treatment of patients with relapsed or refractory multiple myeloma.
April 22nd,2024
Lymphoma , Hematological Neoplasms